Renovaro Inc
RENB
$0.66
Closing
▲5.51%
1D
▼-79.34%
YTD
RENB
BBG0060CNMH7
Market cap
$96.62M
52 week high
$5.25
52 week low
$0.43
Volume
23,983
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$96.62M
Analysts' Rating
-
Price Target (Mean)
0.00
Total Analysts
0
P/E
Operating Margin
0.00%
Beta
0.56
Revenue Growth
0.00%
52 week high
$5.25
52 week low
$0.43
Div. Yield
%
EPS Growth
0.00
Company Profile
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
